Latest Breaking News On - Label extension - Page 1 : vimarsana.com

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew zealandUnited statesGreat britainKristin bhavnaniEpidiolex epidyolexAndrean flynnRob iannoneEuropean unionAccess programPregnancy surveillance programEuropean commissionExchange commissionTherapeutic goods administrationWorld idiopathic hypersomnia total health modelRegulatory agency

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

- Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations for.

United statesUnited kingdomJoshua cohenJustin kleeCamillel bedrosianFumihiko uranoEurope european unionDrug administrationExchange commissionDivision of endocrinologyAmerican academy of neurologyAmylyx pharmaceuticalsHealth canadaAmylyx pharmaceuticals incLabel extensionAmerican academy

Form 8-K Amylyx Pharmaceuticals, For: Apr 03

Form 8-K Amylyx Pharmaceuticals, For: Apr 03
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHealth canadaAmylyx pharmaceuticals incAmylyx pharmaceuticals announces formal intention to removeDrug administrationSecurities exchangeDisposal activitiesAmylyx pharmaceuticalsRestructuring planPharmaceuticals announces formal intentionProvides updatesCorporate restructuringCurrent reportSecurities exchange actSecurities actExchange act

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease SAN DIEGO,.

United statesBuenos airesDistrito federalJula inrigExchange commissionAmerican nephrology nurses associationEuropean commissionNational symposium in orlandoWorld congressTravere therapeutics incNational symposiumSubgroup analysesYear resultsPivotal phaseMain foyerFirst line treatment

Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy

Company Poised for Pivotal Trial Results and FDA Discussions in 2024

Linda marbanCapricor therapeutics incNational institute of allergyExosome technologyFinancial performanceDistribution agreementOrphan drug designationPriority review voucherNational instituteInfectious diseasesLabel extension